Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.4052W HIGH $13.22
Volume
468.40 K
Value Traded
7.47 M
Short % Float
10.68%
Days to Cover
6.1
-1.22%Week
+4.06%1 Month
-22.58%3 Month
-34.01%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
202.56 M
EPS (TTM)
-1.13
P/E Ratio
-
Ent. Value
-6.24 M
Total Shares
41.58 M
Float Shares
38.58 M
Insiders
7.24%
Institutions
103.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RXST Catalyst Timeline
Dated clinical, regulatory and corporate events for RxSight, Inc.
Past FDA Catalysts and PDUFA Decisions
How RXST actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
RxSight, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RXST program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Weinberg EricOfficer (See remarks) | Option | 35,168 235,516 held | $4.34 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RXST
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.2 % (-33.3 %) | 1.54 M | 249.99 K | -28.91% ( -101.67 K) |
RXST Institutional Ownership Trends
RXST Short Interest
Shares sold short, counted twice a month.
10.68%
Short % of Float
of tradable shares sold short
4.1M
Shares Sold Short
+0.8% vs prior count
6.1 High
Days to Cover
trading days of normal volume to buy every short share back
674.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RXST ranks across every disease it competes in
Competitive Position is a premium feature
See how RXST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRXST News
-RXST
Oct 24, 2026RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced the grant of inducement stock options and RSUs to two new employees. The stock options cover 236,456 shares with an exercise price of $5.02, while RSUs covering 637,449 shares are expected to be granted on November 3, 2026. These awards are part of RxSight's strategy to attract talent.
Read more →-RXST
Oct 20, 2026RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
RxSight, Inc. will announce its financial results for the third quarter of 2026 on November 3, 2026. The announcement will be followed by a conference call at 1:30 p.m. PT. Investors can participate via phone or listen online, with an archived recording available afterward.
Read more →-RXST
Oct 19, 2026RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
RxSight, Inc. has appointed Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy. These appointments aim to enhance the company's commercial execution and accelerate the adoption of its Light Adjustable Lens technology. The new leaders bring extensive experience in eye care and commercial strategy, supporting RxSight's goal of deeper customer engagement.
Read more →-RXST
Aug 26, 2026RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
RxSight, Inc. will participate in the Wells Fargo Healthcare Conference on September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. The company specializes in ophthalmic medical devices, particularly the Light Adjustable Lens system, which allows for post-surgery adjustments to enhance patient vision. A webcast of the presentation will be available on their investor relations website.
Read more →-RXST
Aug 5, 2026RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. reported its second quarter 2026 financial results, highlighting a revenue of $33.7 million, including $6.5 million from a collaboration with Alcon. The company appointed Aziz Mottiwala as CEO and announced a strategic partnership aimed at developing new intraocular lenses. However, product sales fell by 19%, prompting the withdrawal of 2026 guidance.
Read more →-RXST
Jul 15, 2026▲ +6.1%on this news
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
RxSight, Inc. has announced the appointment of Aziz Mottiwala as the new CEO, effective July 20, 2026, succeeding Ron Kurtz, M.D., who will remain as Chief Medical Officer. Mottiwala has a strong background in commercial leadership within the eye care sector. The transition aims to leverage his expertise to enhance RxSight's innovative adjustability technology in cataract surgery.
Read more →-RXST
Jul 6, 2026Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight have announced a collaboration aimed at developing adjustable posterior chamber intraocular lenses (PCIOLs). This partnership is expected to leverage both companies' expertise in ophthalmic technologies. Details regarding the timeline and specific goals of the collaboration have not been disclosed.
Read more →-RXST
Jul 6, 2026RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
RxSight, Inc. has announced preliminary financial results for Q2 2026, projecting revenues between $32 to $34 million, including $5 to $7 million from a collaboration with Alcon. The company is advancing its product pipeline with next-generation light-adjustable lenses, despite facing competitive challenges. RxSight maintains a strong cash position of approximately $209 million.
Read more →-RXST
May 19, 2026RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. will present at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026. Management will participate in a fireside chat at 10:00 a.m. Pacific Time. The event will be accessible via a live and archived webcast on the company's investor relations website.
Read more →-RXST
May 6, 2026▼ -6.6%on this news· ran to -21% by day 3
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
RxSight, Inc. reported Q1 2026 sales of $30.9 million, an 18.5% decline year-over-year. The company highlighted robust clinical data from the ASCRS meeting and received regulatory approval in New Zealand. Despite the decrease in sales and an increased net loss, RxSight maintained its full-year sales outlook and gross margin guidance.
Read more →-RXST
Apr 29, 2026▼ -5%on this news
RxSight, Inc. to Present at the Bank of America Healthcare Conference
RxSight, Inc. has announced its participation in the Bank of America Healthcare Conference, scheduled for May 13, 2026. The management will engage in a fireside chat, highlighting the company's innovative ophthalmic medical devices. The event will be accessible via a live and archived webcast on their investor relations website.
Read more →-RXST
Apr 22, 2026RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. will announce its first-quarter financial results on May 6, 2026, after market close. The management will hold a conference call at 1:30 p.m. PT to discuss these results. Participants can join the call via phone or listen online. The company focuses on advanced ophthalmic devices for cataract surgery.
Read more →-RXST
Apr 3, 2026▲ +5.7%on this news
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. has announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management will engage in a fireside chat scheduled for April 16, 2026, at 8:00 a.m. Pacific Time. The event will be accessible via a live and archived webcast on the company's investor relations website.
Read more →-RXST
Feb 26, 2026▼ -10.1%on this news
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
RxSight, Inc. reported its financial results for Q4 and the full year 2025, highlighting a 4% decrease in global sales to $134.5 million. While LAL revenue grew by 12%, this was overshadowed by a 48% decline in LDD system sales. The company also announced a net loss of $(38.9) million for the year, with a focus on expanding its commercial initiatives and international presence.
Read more →-RXST
Jan 11, 2026▲ +14.1%on this news
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer Aliso Viejo, Calif. (Nasdaq: RXST) –
RxSight, Inc. has announced preliminary unaudited financial results for Q4 and the full year 2025, indicating an increase in revenue and procedure volume. The company has appointed Mark Wilterding as the new Chief Financial Officer, expected to enhance financial operations moving forward. Despite positive indicators, results remain preliminary and are subject to an audit, suggesting some uncertainty in the reported figures. RxSight continues to strengthen its position in the cataract surgery market with growing adoption of its adjustable intraocular lens technology.
Read more →-RXST
Dec 22, 2025RXSIGHT, INC. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION
RxSight, Inc. has announced that Shelley Thunen, the Chief Financial Officer, will transition from her role while continuing to support the company as a consultant. Thunen has been instrumental in RxSight's growth, guiding the company through pivotal financial milestones including its IPO in 2021. The leadership recognized her significant contributions in developing the company's financial strategy and achieving over 1,100 Light Delivery Devices in the field and a quarter million procedures performed. A successor will be appointed before her departure on January 31, 2026.
Read more →-RXST
Nov 5, 2025▼ -7.3%on this news
RXSIGHT, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
RxSight, Inc. reported its financial results for the third quarter of 2025, revealing a 14% decrease in revenue to $30.3 million compared to the same period in 2024. The company experienced a 6% increase in the sale of Light Adjustable Lenses (LAL) but faced a significant decline in sales of Light Delivery Devices (LDD), which dropped by 68%. Despite the challenges, RxSight improved its gross margin to 80% and has narrowed its revenue guidance for the full year 2025, suggesting a strategic focus on profitability and operational efficiency. The company continues to invest in its commercial infrastructure and aims to stabilize the procedures in its market segment.
Read more →-RXST
Aug 7, 2025RXSIGHT, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
RxSight, Inc. reported its financial results for the second quarter of 2025, revealing total revenues of $33.6 million, a decrease of 4% from the prior year. Despite a 13% increase in revenue from Light Adjustable Lenses, sales of Light Delivery Devices saw a significant decline of 49%. The company received FDA approval for expanding its product range and launched the RxSight system in South Korea, aiming for strategic growth. Net loss in Q2 2025 rose to $(11.8) million, up from $(6.1) million in Q2 2024.
Read more →-RXST
Aug 4, 2025RXSIGHT, INC. APPOINTS RAYMOND W. COHEN TO ITS BOARD OF DIRECTORS
RxSight, Inc. has appointed Raymond W. Cohen to its Board of Directors, a move expected to enhance the company's growth and strategy in the ophthalmic medical device market. Cohen brings over four decades of experience in medical technology, previously co-founding Axonics, Inc. which achieved substantial revenue growth. He expressed confidence in RxSight's potential to expand its reach within the premium intraocular lens market, leveraging its unique Light Adjustable Lens system. This appointment reflects RxSight's commitment to providing customized vision solutions for cataract surgery patients.
Read more →About RxSight, Inc.
Headquarters100 COLUMBIA STREET, ALISO VIEJO, CA, 92656
BIOPHARMAWATCH ELITE PLUS
Trade the next RXST catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime